Methods of healing wounds and fibrotic disorders using IL-10

• US 6,387,364 B1
• Filed: 05/01/2000
• Issued: 05/14/2002
• Est. Priority Date: 08/09/1995
• Status: Expired due to Term

• Current Assignee: Armo BioSciences Inc. (Eli Lilly and Company), Queen's University
• Original Assignee: Renovo Ltd. (Bentley Park Ltd.)
• Inventors: Ferguson, Mark W. J.
• Primary Examiner(s): Kunz, Gary L.
• Assistant Examiner(s): Landsman, Robert S.
• Application Number:
  US09/011,027
• Time in Patent Office: 743 Days
• Field of Search: 514/2, 530/300, 530/350, 424/85.2
• US Class Current: 424/85.2
• CPC Class Codes: A61K 38/2066 IL-10
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention provides IL-10 or a fragment or a partially modified form thereof, for use in promoting the healing of wounds and fibrotic disorders with reduced scarring and methods for same.

Claims

1. A method for promoting the healing of a wound with reduced scarring comprising administering to a subject in need of treatment a therapeutically effective amount of human IL-10 wherein said administration is at the site of said wound.

2. The method according to claim 1 wherein the IL-10 is administered to a wound site.

3. The method according to claim 2, wherein the IL-10 is administered at a concentration of between about 1 μ

M and about 10 μ

M.

4. The method according to claim 3 wherein the IL-10 is administered at a concentration of between about 2.5 μ

M and about 5 μ

M.

5. A method for promoting the healing of a fibrotic disorders with reduced scarring comprising administering to a subject in need of treatment a therapeutically effective amount of human IL-10 wherein said administration is at the site of said disorder.

6. The method according to claim 5 wherein the IL-10 is administered to a site of a fibrotic disorder.

7. The method according to claim 6, wherein the IL-10 is administered at a concentration of between about 1 μ

M and about 10 μ

M.

8. The method according to claim 7 wherein the IL-10 is administered at a concentration of between about 2.5 μ

M and about 5 μ

M.